ABBV-321 in Advanced Solid Tumors with Overexpression of EGFR - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
Adults who are diagnosed with colorectal cancer or glioblastoma.
What is Involved?
There are two phases to this study:
Phase 1 is where the study drug ABBV-321 will be given through a vein once every 28 days and will be given in higher doses until we can get the highest and safest dose.
Phase 2 is where patients will be watched for side effects (good or bad) of the study drug ABBV-321 (given through a vein) at the dose found in Phase 1.